Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about NRXP, unsubscribe in one click. Privacy
NRXP holds $26.7M in cash and short-term investments (as of Jun 30, 2026) and burns about $6.6M/quarter from operations, an estimated runway of 12.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 53 · Elevated
As such, the Company has concluded that substantial doubt exists regarding the Company’s ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NRXP files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NRXP and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →